Edgestream Partners, L.P. Denali Therapeutics Inc. Transaction History
Edgestream Partners, L.P.
- $3.32 Billion
- Q3 2025
A detailed history of Edgestream Partners, L.P. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 123,819 shares of DNLI stock, worth $2.16 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
123,819
Previous 342,923
63.89%
Holding current value
$2.16 Million
Previous $4.8 Million
62.54%
% of portfolio
0.05%
Previous 0.14%
Shares
3 transactions
Others Institutions Holding DNLI
# of Institutions
259Shares Held
133MCall Options Held
219KPut Options Held
107K-
Black Rock Inc. New York, NY13.2MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$209 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$202 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.64MShares$98.3 Million0.05% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL5.47MShares$95.3 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.34B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...